Gilead Sciences Inc (GILD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Gilead Sciences Inc stock (GILD) is currently trading at $138.26. Gilead Sciences Inc PE ratio is 20.37. Gilead Sciences Inc PS ratio (Price-to-Sales) is 5.82. Analyst consensus price target for GILD is $157.43. WallStSmart rates GILD as Moderate Buy.
Gilead Sciences Inc (GILD) stock price prediction for 2030: Base case $134.54. Bull case $168.18. Bear case $100.91. See full GILD 2030 price forecast and methodology on WallStSmart.
- GILD PE ratio analysis and historical PE chart
- GILD PS ratio (Price-to-Sales) history and trend
- GILD intrinsic value — DCF, Graham Number, EPV models
- GILD stock price prediction 2025 2026 2027 2028 2029 2030
- GILD fair value vs current price
- GILD insider transactions and insider buying
- Is GILD undervalued or overvalued?
- Gilead Sciences Inc financial analysis — revenue, earnings, cash flow
- GILD Piotroski F-Score and Altman Z-Score
- GILD analyst price target and Smart Rating
Gilead Sciences Inc
📊 No data available
Try selecting a different time range
GILD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Gilead Sciences Inc (GILD)
GILD trades at a significant discount to its Graham intrinsic value of $299.95, offering a 54% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Gilead Sciences Inc (GILD) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Concerns around price/book and revenue growth. Overall metrics suggest strong investment potential with favorable risk/reward.
Gilead Sciences Inc (GILD) Key Strengths (7)
Growing significantly faster than its price suggests
Every $100 of shareholder equity generates $41 in profit
Keeps $37 of every $100 in revenue after operating costs
Keeps $29 of every $100 in revenue as net profit
92.61% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong earnings growth at 23.40% per year
Gilead Sciences Inc (GILD) Areas to Watch (3)
Very expensive at 7.5x book value
Revenue growing slowly at 4.70% annually
Premium valuation at 5.8x annual revenue
Supporting Valuation Data
Gilead Sciences Inc (GILD) Detailed Analysis Report
Overall Assessment
This company scores 72/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 7 register as strengths (avg 9.6/10) while 3 fall into concern territory (avg 2.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Return on Equity, Operating Margin. Valuation metrics including PEG Ratio (0.38) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 40.70%, Operating Margin at 37.40%, Profit Margin at 28.90%. Growth metrics are encouraging with EPS Growth at 23.40%.
The Bear Case
The primary concerns are Price/Book, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (5.82), Price/Book (7.50) suggest expensive pricing. Growth concerns include Revenue Growth at 4.70%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 40.70% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 4.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of PEG Ratio and Return on Equity makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GILD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GILD's Price-to-Sales ratio of 5.82x trades at a deep discount to its historical average of 12.22x (27th percentile). The current valuation is 89% below its historical high of 52.8x set in Sep 2006, and 99% above its historical low of 2.93x in May 2017.
Compare GILD with Competitors
Top DRUG MANUFACTURERS - GENERAL stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Gilead Sciences Inc (GILD) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Gilead Sciences Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 29.4B with 470% growth year-over-year. Profit margins are strong at 28.9%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 470% YoY, reaching 29.4B. This pace significantly outperforms most DRUG MANUFACTURERS - GENERAL peers.
ROE of 4070.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Gilead Sciences Inc maintain 470%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Gilead Sciences Inc.
Bottom Line
Gilead Sciences Inc offers an attractive blend of growth (470% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(67 last 3 months)
| Insider | Type | Shares |
|---|---|---|
GILEAD, SCIENCES, INC. 10% Owner | Buy | +3,739,000 |
| Insider | Type | Shares |
|---|---|---|
O'DAY, DANIEL PATRICK Director, Chairman & CEO | Sell | -10,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:27:48 AM
About Gilead Sciences Inc(GILD)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.